Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix in Adults with Prior Herpes Zoster
NCT01827839Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2013
- Primary completion
- Feb 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of herpes zoster vaccine (recombinant, adjuvanted) in herpes zoster (HZ), sponsored by GSK. Primary endpoints: Number of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA at Month 3, Number of Subjects With Any and Grade 3 Solicited Local Symptoms and 6 more. Started Jun 2013; status: completed.
02
Drugs
herpes zoster vaccine (recombinant, adjuvanted)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT01827839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827839.